Bank of America Corp DE Lowers Holdings in Medline $MDLN

Key Points

• Bank of America reduced its Medline position by 9.5% in the first quarter, selling 238,909 shares and retaining 2.29 million shares worth approximately $101.8 million.
• Medline reported strong quarterly results, with $0.50 in earnings per share versus a $0.32 consensus estimate and roughly $7.69 billion in revenue. The company raised its 2026 organic-sales-growth outlook to 9%–10%, but lowered its adjusted EBITDA forecast to $3.3 billion–$3.4 billion, indicating potential margin pressure.
• Analysts remain broadly positive, with a “Moderate Buy” consensus and an average price target of $48.50 versus a recent share price near $35.23. However, substantial insider and major-shareholder selling, along with reported FDA-related investigations, presents potential sentiment and regulatory risks.

Bank of America Corp DE reduced its position in Medline (NASDAQ:MDLN - Free Report) by 9.5% in the first quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund owned 2,288,251 shares of the company's stock after selling 238,909 shares during the period. Bank of America Corp DE owned about 0.17% of Medline worth $101,827,000 at the end of the most recent reporting period.

A number of other hedge funds have also bought and sold shares of MDLN. Sound Income Strategies LLC bought a new position in shares of Medline in the 4th quarter worth approximately $25,000. Entrust Financial LLC bought a new stake in Medline during the 4th quarter worth approximately $26,000. NBC Securities Inc. purchased a new position in Medline during the fourth quarter valued at approximately $28,000. Whipplewood Advisors LLC bought a new position in shares of Medline in the first quarter worth approximately $30,000. Finally, Global Retirement Partners LLC bought a new position in shares of Medline in the fourth quarter worth approximately $31,000.

More Medline News

Here are the key news stories impacting Medline this week:

• Positive Sentiment: Medline reported second-quarter earnings of $0.50 per share, well above the $0.32 analyst consensus, on $7.69 billion in revenue. The company also raised its 2026 organic-sales-growth outlook to 9%–10%, signaling continued demand for its medical-supply products. Medline Q2 Earnings Snapshot Medline raises 2026 organic sales outlook
• Positive Sentiment: Analysts remain constructive: BTIG reiterated a Buy rating with a $55 price target, while Truist and Stifel maintained Buy ratings with targets of $47 and $45, respectively. Although both firms reduced their targets, they still imply substantial upside from recent levels. BTIG Medline rating
• Neutral Sentiment: The positive sales outlook was accompanied by a reduction in projected 2026 adjusted EBITDA to $3.3 billion–$3.4 billion. This suggests strong revenue momentum but near-term margin or cost pressures that could limit earnings growth.
• Negative Sentiment: Major shareholder GIC Private Ltd. sold approximately 2.25 million Medline shares across August 5–6 for roughly $80 million, reducing its holdings by about 8.3% overall. Large-holder selling can add supply and weigh on investor sentiment. SEC ownership filing
• Negative Sentiment: Several law firms announced investigations into potential securities-law violations following previously reported FDA violations. The announcements do not establish wrongdoing, but they introduce potential legal, regulatory, and reputational risks for Medline. Kaplan Fox Medline investigation Kessler Topaz Medline investigation

Insider Buying and Selling

In related news, major shareholder Private Ltd Gic sold 271,994 shares of the business's stock in a transaction on Thursday, August 6th. The stock was sold at an average price of $35.33, for a total transaction of $9,609,548.02. Following the completion of the transaction, the insider owned 24,992,766 shares in the company, valued at $882,994,422.78. The trade was a 1.08% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, insider Douglas P. Golwas sold 100,000 shares of the company's stock in a transaction on Tuesday, June 16th. The shares were sold at an average price of $36.77, for a total value of $3,677,000.00. Following the completion of the transaction, the insider directly owned 23,899 shares in the company, valued at $878,766.23. This trade represents a 80.71% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. In the last three months, insiders sold 2,348,612 shares of company stock valued at $83,654,149. Insiders own 0.81% of the company's stock.

Medline Stock Performance

NASDAQ MDLN opened at $35.23 on Friday. The company has a market cap of $46.28 billion and a P/E ratio of 110.09. The company has a debt-to-equity ratio of 0.66, a quick ratio of 2.51 and a current ratio of 4.33. The business's 50 day moving average price is $38.22 and its 200-day moving average price is $41.72. Medline has a fifty-two week low of $32.81 and a fifty-two week high of $50.88.

Medline (NASDAQ:MDLN - Get Free Report) last announced its earnings results on Wednesday, August 5th. The company reported $0.50 earnings per share for the quarter, beating the consensus estimate of $0.32 by $0.18. The firm had revenue of $7.68 billion during the quarter. Sell-side analysts predict that Medline will post 1.49 earnings per share for the current year.

Wall Street Analysts Forecast Growth

MDLN has been the topic of several research analyst reports. Royal Bank Of Canada lowered their price objective on Medline from $53.00 to $46.00 and set an "outperform" rating on the stock in a research report on Thursday. Tigress Financial boosted their price target on Medline from $60.00 to $62.00 and gave the stock a "buy" rating in a report on Wednesday, May 13th. Citigroup dropped their price target on Medline from $60.00 to $55.00 and set a "buy" rating for the company in a research note on Thursday, May 7th. Sanford C. Bernstein dropped their target price on shares of Medline from $56.00 to $54.00 and set an "outperform" rating for the company in a research report on Thursday, May 7th. Finally, Stifel Nicolaus dropped their price objective on shares of Medline from $50.00 to $45.00 and set a "buy" rating for the company in a report on Thursday. One equities research analyst has rated the stock with a Strong Buy rating, twenty-two have assigned a Buy rating, five have assigned a Hold rating and one has issued a Sell rating to the company's stock. Based on data from MarketBeat.com, the company currently has an average rating of "Moderate Buy" and an average price target of $48.50.

Medline Company Profile

Medline NASDAQ: MDLN is a healthcare products and services company that manufactures, sources and distributes a wide range of medical supplies and equipment for healthcare providers. Its product portfolio spans clinical consumables and personal protective equipment, surgical and procedural supplies, wound care and incontinence products, diagnostic and laboratory supplies, and select durable medical equipment. Medline supports care settings that include hospitals, health systems, long-term care facilities, ambulatory clinics and home health providers.

In addition to product manufacturing and distribution, Medline provides supply‑chain and logistics services designed to help healthcare customers manage inventory, reduce costs and streamline operations.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source